Innovus Pharmaceuticals Inc. (fka INNV)

[ShawnP123]

NT- Blaming the MM's and the buyers for playing the short plays is just an excuse. The problem with the stock falls on Damaj.

1) Dilution
2) Making statements which don't happen (FDA approval since late
2015
3) Lack of growth from the latest quarter to quarter.
4) Potential buyers of this stock currently have nothing to
support a decision to buy and hold for any length of time.

Let's see how good Damaj's claim is from one of the latest CC's regarding Q3 is the best quarter. He's had enough time on many of the new products and also made some claims about annual sales for some of those. If Q3 comes in under $2.6- 2.7M, don't expect much. For Q4, it will be interesting to see if Damaj had a customer and PO for Fluticare If so, it should show up on the Revs. If not, Q4 will be a big let down and most likely kill the stock until Mid 2018. By then, he'll have to float more stock to continue.